Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial
Andresen V, Gschossmann J, Layer P
Published in The Lancet Gastroenterology & Hepatology
Abstract
Multicentre randomised double-blind placebo-controlled trial of heat-inactivated Bifidobacterium bifidum MIMBb75 in IBS.
Key Findings
Heat-inactivated B. bifidum MIMBb75 achieved the composite responder endpoint in 34% of patients versus 19% on placebo over 8 weeks.
Conclusions
Even non-viable B. bifidum MIMBb75 improves IBS symptoms, supporting a postbiotic mechanism.
Limitations
Manufacturer-funded; 8-week duration; applies to one specific preparation.
Supplements Studied
Heat-inactivated B. bifidum MIMBb75 achieved the composite responder endpoint in 34% of patients versus 19% on placebo over 8 weeks.
Outcomes Measured
Heat-inactivated B. bifidum MIMBb75 achieved the composite responder endpoint in 34% of patients versus 19% on placebo over 8 weeks.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.